A novel model to study COVID-19 and Hypertension

NIH RePORTER · NIH · R21 · $193,125 · view on reporter.nih.gov ↗

Abstract

7. Project Summary/Abstract Animal models fare indispensable for understanding the pathology of COVID-19 as well as for developing vaccines. They are also important to discern the etiology of COVID-19 in specific groups at risk, such as individuals with pre-existing hypertension. While there are hamsters, ferrets, cats, nonhuman primates and K18- hACE2 transgenic mice as possible models for studying COVID-19, none serves the purpose of studying the relationship between hypertension and susceptibility to COVID-19 because (1) wild-type research models do not get infected with the human SARS-CoV-2 and/or (2) they are not genetically prone to hypertension. To fill this unmet need, we propose to develop in vivo experimental platform for studying COVID-19 in the setting of hypertension. In preliminary data, we present evidence for the development of a novel knock-in rat model of the hypertensive Dahl Salt-sensitive (S) rat edited using the CRISPR/Cas9 technology to express the human ACE2 gene (hACE2), which is the receptor for SARS-CoV-2. The gene hACE2 is inserted to replace the rat Ace2 locus. The required rat Ace2 knockout as the control strain (rAce2-KO) has also been generated. By comparing these 2 strains, in Aim 1 we will examine the suitability of this rat model for studying COVID-19. Further, based on our recent published work using germ-free rats indicating that introduction of microbiota to germ-free rats upregulated colonic Ace2 expression and blood pressure combined with the existing knowledge of a strong relationship between salt-sensitive hypertension and the gut microbiota; in Aim 2, we will test the hypothesis that the loss of normal symbiosis between the host and gut microbiota during a hypertensive state is responsible for the lower ACE2 expression in multiple organs.

Key facts

NIH application ID
10428648
Project number
5R21AI164449-02
Recipient
UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS
Principal Investigator
BINA JOE
Activity code
R21
Funding institute
NIH
Fiscal year
2022
Award amount
$193,125
Award type
5
Project period
2021-06-14 → 2023-05-31